Protective Effects of a Novel Agonist of Galanin Receptors Against Doxorubicin-Induced Cardiotoxicity in Rats
- 20 September 2018
- journal article
- research article
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 19 (2) , 136-146
Abstract
The clinical use of antineoplastic agent doxorubicin (DOX) is limited due to its cardiotoxic action. [βAla14, His15]-galanine (2–15) (G) is a novel synthetic agonist of galanin receptors GalR1-3 having cardioprotective properties in animal models in vivo. The aim of the present study was to explore effects of G on DOX-induced cardiotoxicity. Wistar rats were divided into four groups and treated with DOX (D group), DOX and G (D + G group), G (G group), and saline (control). Before treatment and at the end of the study, concentration of thiobarbituric acid reactive substances (TBARS) and activity of creatine kinase-MB (CK-MB) were determined in blood plasma, the animals were weighed, and cardiac function was evaluated by echocardiography. At the end of experiments, the hearts were used to determine energy metabolites and mitochondrial respiration in permeabilized fibers. After an 8-week study, D group exhibited a pronounced cardiac failure, the absence of weight gain, an increased plasma TBARS concentration, and CK-MB activity. These disorders were accompanied by a reduced myocardial content of high-energy phosphates and mitochondrial respiratory parameters. Co-administration of G with DOX significantly decreased plasma TBARS level and prevented an increase in plasma CK-MB activity. In D + G group, myocardial contents of ATP, PCr, total adenine nucleotides, and total creatine as well as myocardial PCr/ATP ratio and the respiratory control index were higher than in D group at the end of the experiments. Peptide G significantly improved parameters of left ventricular (LV) function and caused weight gain in animals of D + G group. These results suggest that peptide G may be a potential pharmacological agent that attenuates the cardiotoxic effects of DOX.Keywords
Funding Information
- Russian Foundation for Basic Research (18-015-00008)
This publication has 38 references indexed in Scilit:
- Identification of the molecular basis of doxorubicin-induced cardiotoxicityNature Medicine, 2012
- Galanin Receptors and LigandsFrontiers in Endocrinology, 2012
- Diet‐induced obesity regulates the galanin‐mediated signaling cascade in the adipose tissue of miceMolecular Nutrition & Food Research, 2010
- Molecular characterization of the ligand binding site of the human galanin receptor type 2, identifying subtype selective interactionsJournal of Neurochemistry, 2007
- The galanin peptide family: Receptor pharmacology, pleiotropic biological actions, and implications in health and diseasePharmacology & Therapeutics, 2007
- Dexrazoxane prevents doxorubicin‐induced long‐term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in ratsBritish Journal of Pharmacology, 2007
- Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancerAnti-Cancer Drugs, 2003
- Differences in nucleotide compartmentation and energy state in isolated and in situ rat heart: Assessment by 31P-NMR spectroscopyBiochimica et Biophysica Acta (BBA) - Bioenergetics, 1996
- The relationship between cardiac function and metabolism in acute adriamycin-treated perfused rat hearts studied by 31P and 13C NMR spectroscopyJournal of Molecular and Cellular Cardiology, 1990
- Effects of the anti-cancer drug adriamycin on the energy metabolism of rat heart as measured by in vivo 31P-NMR and implications for adriamycin-induced cardiotoxicityBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1987